Surgical resection of primary cardiac sarcoma resulted in a median survival of 3.0 years, with estimated survival at 1, 5, and 10 years of 73%, 31%, and 17%, respectively.
Cohort (n=32)
No
Surgical resection of primary cardiac sarcoma can be performed with zero operative mortality and provides a median survival of 3 years, though recurrence rates remain high and necessitate rigorous surveillance.
Objective: To evaluate the outcomes of surgical resection of malignant primary cardiovascular tumors. Methods: From 1983 to 2018, 32 patients underwent surgical resection of malignant primary cardiovascular sarcoma at Cleveland Clinic. Mean age was 48 ± 15 years, and 19 (59%) were women. Outcomes are compared between those with complete resection and those without, and in relation to primary location. Results: The most common histologic subtypes were angiosarcoma (n = 8 25%) and high-grade undifferentiated sarcoma (n = 7 22%). Fourteen (44%) involved the left heart, 9 (28%) the right heart, 8 (25%) the pulmonary arteries, and 1 (3%) the aorta. There was clinical evidence of isolated extracardiac metastases in 8 (25%). Six (19%) patients were deemed unresectable at surgery, undergoing biopsy and palliative debulking followed by referral for definitive chemotherapy and/or radiation. The remaining 26 (81%) patients underwent 31 tumor resections with curative intent. Seven (22%) patients had previously undergone a resection or biopsy at another institution. There were 10 second-time resections, 2 third-time resections, 1 fourth-time resection, and no operative mortalities. Median survival was 3 years, with estimated survival at 6 months and 1, 5, and 10 years of 90%, 73%, 31%, and 17%, respectively. Of the 8 (25%) who were considered disease-free following surgery, 4 experienced recurrences during follow-up. Conclusions: Primary cardiac sarcoma continues to be a challenging disease with poor prognosis. Aggressive resection with curative intent, frequent surveillance for local and distant recurrence, and systemic and local multimodality treatment optimizes outcomes.
Hasan et al. (Fri,) conducted a cohort in Malignant primary cardiovascular sarcoma (n=32). Surgical resection was evaluated on All-cause mortality (median survival in years) (95% CI 1.08-4.7). Surgical resection of primary cardiac sarcoma resulted in a median survival of 3.0 years, with estimated survival at 1, 5, and 10 years of 73%, 31%, and 17%, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: